Disease · HP_0003419
Low back pain
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. Low back pain. Diseases, record HP_0003419. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0003419
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Low back pain
- Open Targets ID
- HP_0003419
- Other names
- LBP, Lower back pain, Lumbago
- Highest stage of its drugs
- Approval, for 1 of its 117 drugs, from PMDA
Source Open Targets
Drugs117
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BUPRENORPHINE | CHEMBL511142 | Small molecule | Approval | PMDA | 7 | 6 | 6 | Drugs and targets |
| ACETAMINOPHEN | CHEMBL112 | Small molecule | Phase 3 | ClinicalTrials.gov | 12 | 12 | 12 | Drugs and targets |
| IBUPROFEN | CHEMBL521 | Small molecule | Phase 3 | ClinicalTrials.gov | 10 | 10 | 6 | Drugs and targets |
| LIDOCAINE | CHEMBL79 | Small molecule | Phase 3 | ClinicalTrials.gov | 10 | 10 | 10 | Drugs and targets |
| OXYCODONE | CHEMBL656 | Small molecule | Phase 3 | ClinicalTrials.gov | 10 | 10 | 10 | Drugs and targets |
| CELECOXIB | CHEMBL118 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 4 | Drugs and targets |
| TRAMADOL | CHEMBL1237044 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| DICLOFENAC SODIUM | CHEMBL1034 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| ETORICOXIB | CHEMBL416146 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
1 to 10 of 117
See all 117 drugsTargets144
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| OPRM1 | Mu-type opioid receptor | 18 | Mu opioid receptor agonist; Opioid receptors; mu/kappa/delta agonist; Opioid receptors; mu/kappa/delta antagonist | Approval | https://conductscience.org/library/genes/4988 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 13 | Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor | Phase 3 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 12 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| OPRK1 | Kappa-type opioid receptor | 10 | Kappa opioid receptor agonist; Opioid receptors; mu/kappa/delta agonist; Opioid receptors; mu/kappa/delta antagonist | Approval | https://conductscience.org/library/genes/4986 | Drugs and targets |
| OPRD1 | Delta-type opioid receptor | 8 | Delta opioid receptor agonist; Opioid receptors; mu/kappa/delta agonist; Opioid receptors; mu/kappa/delta antagonist | Phase 3 | https://conductscience.org/library/genes/4985 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 8 | Cyclooxygenase inhibitor | Phase 3 | https://conductscience.org/library/genes/5742 | Drugs and targets |
| SLC6A2 | Monoamine transporter | 7 | Monoamine transporter inhibitor; Norepinephrine transporter inhibitor | Phase 3 | https://conductscience.org/library/genes/6530 | Drugs and targets |
| GABRA1 | GABA A receptor alpha-1/beta-1/gamma-2 | 4 | GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRB1 | GABA A receptor alpha-1/beta-1/gamma-2 | 4 | GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2560 | Drugs and targets |
| GABRG2 | GABA A receptor alpha-1/beta-1/gamma-2 | 4 | GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2566 | Drugs and targets |
1 to 10 of 144
See all 144 targetsTrials156
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 9 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02528253 | A Phase 3 Study of Tanezumab for Chronic Low Back Pain | Phase 3 | 1,832 | 2020-02-21 | Low Back Pain | TANEZUMAB, TRAMADOL | Its record names the disease | ClinicalTrials.gov |
| NCT00876187 | A Study of Tanezumab in Adults With Chronic Low Back Pain | Phase 2 | 1,359 | 2021-07-07 | Low Back Pain | NAPROXEN, TANEZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02362672 | Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain | Phase 3 | 1,189 | 2020-09-16 | Low Back Pain, Chronic Pain | OXYCODEGOL | Its record names the disease | ClinicalTrials.gov |
| NCT01452529 | Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain | Phase 3 | 905 | 2014-12-04 | Chronic Low Back Pain | HYDROCODONE BITARTRATE | Its record names the disease | ClinicalTrials.gov |
| NCT00924664 | Long Term Safety Study of Tanezumab in Chronic Low Back Pain | Phase 2 | 849 | 2021-04-21 | Low Back Pain | TANEZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01708915 | Nonivamide/Nicoboxil Ointment in Acute Low Back Pain | Phase 3 | 805 | 2014-05-15 | Acute Low Back Pain | NICOBOXIL, NONIVAMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01685684 | Oxycodone DETERx™ Versus Placebo in Chronic Low Back Pain (CLBP) | Phase 3 | 740 | 2017-02-23 | Chronic Low Back Pain | OXYCODONE | Its record names the disease | ClinicalTrials.gov |
| NCT00986180 | NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain | Phase 3 | 667 | 2012-02-29 | Pain, Back Pain, Low Back Pain, Back Pain With Radiation | OXYCODONE, TAPENTADOL | Its record names the disease | ClinicalTrials.gov |
| NCT00313014 | Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain | Phase 3 | 660 | 2010-09-29 | Back Pain Lower Back Chronic | BUPRENORPHINE, OXYCODONE | Its record names the disease | ClinicalTrials.gov |
| NCT03003000 | Ibuprofen/Caffeine Lower Back or Neck Pain Study | Phase 3 | 635 | 2019-06-07 | Back Pain, Neck Pain | CAFFEINE, IBUPROFEN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 156
See all 156 trialsComparisons in its trials56
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Tanezumab 10 mg vs Tanezumab 20 mg: Number of Participants Using Concomitant Medication for Chronic Low Back Pain (CLBP) | 150 of 321 | 268 of 527 | 848 | NCT00924664 | Trial comparisons |
| Tanezumab 10 mg vs Tanezumab 20 mg: serious adverse events | 15 of 321 | 24 of 527 | 848 | NCT00924664 | Trial comparisons |
| NUCYNTA vs Oxycodone IR: Summary of Subjects Having Nausea as a Treatment-Emergent Adverse Event | 51 of 321 | 67 of 324 | 645 | NCT00986180 | Trial comparisons |
| NUCYNTA vs Oxycodone IR: Summary of Subjects Having Constipation as a Treatment-Emergent Adverse Event | 7 of 321 | 23 of 324 | 645 | NCT00986180 | Trial comparisons |
| NUCYNTA vs Oxycodone IR: Summary of Subjects Having Pruritus as a Treatment-Emergent Adverse Event | 27 of 321 | 26 of 324 | 645 | NCT00986180 | Trial comparisons |
| NUCYNTA vs Oxycodone IR: Summary of Subjects Having Vomiting as a Treatment-Emergent Adverse Event | 51 of 321 | 80 of 324 | 645 | NCT00986180 | Trial comparisons |
| NUCYNTA vs Oxycodone IR: serious adverse events | 2 of 321 | 3 of 324 | 645 | NCT00986180 | Trial comparisons |
| NKTR-181 vs Placebo: Patient Global Impression of Change (PGIC): Number of Responders | 159 of 309 | 100 of 301 | 610 | NCT02362672 | Trial comparisons |
| NUCYNTA vs Oxycodone IR: Incidence of 50% Responders Without Nausea or Vomiting at Day 5 | 72 of 287 | 60 of 298 | 585 | NCT00986180 | Trial comparisons |
| NUCYNTA vs Oxycodone IR: Incidence of 30% Responders Without Nausea or Vomiting at Day 5 | 117 of 287 | 104 of 298 | 585 | NCT00986180 | Trial comparisons |
1 to 10 of 56
See all 56 comparisons in its trialsPapers from its trials90
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0003419
GET https://conductscience.org/api/diseases/v1/HP_0003419/drugs?page=2